Newbury Pharmaceuticals AB Sustainability Reports

Newbury Pharmaceuticals AB operates as a hybrid pharmaceutical company building a pipeline of proprietary and licensed specialty prescription drugs. The company mainly targets the Scandinavian markets with treatment solutions focusing on oncology, rare diseases, and neurology.

Sector: Manufacturing

Country: Sweden

Exchange: Nasdaq Stockholm

LEI: 549300F7XHU3I8CWL373

FIGI: BBG014R9C0T6

4 reports from 2022 to 2025

• Newbury Pharmaceuticals AB 2025 Annual Report and Consolidated Accounts
• Newbury Pharmaceuticals AB 2024 Annual Report and Consolidated Accounts
• Newbury Pharmaceuticals AB 2023 Annual Report and Consolidated Accounts
• Newbury Pharmaceuticals AB 2022 Annual Report and Consolidated Accounts